A hidden immune backup system could supercharge mRNA cancer vaccines
Researchers at Washington University School of Medicine have discovered that mRNA cancer vaccines can remain effective even when certain primary immune cells are absent. The study reveals a backup mechanism where related immune cells compensate to trigger an anti-tumor response.
Why it matters
Understanding these redundant immune pathways could lead to more robust and effective mRNA cancer vaccines, improving treatment outcomes for various malignancies.
The success of mRNA vaccines against SARS-CoV-2 during the COVID-19 pandemic transformed vaccine science. Now, the same Nobel Prize winning technology is being adapted to fight cancer, with experimental mRNA vaccines already being tested against melanoma, small cell lung cancer, bladder cancer, and several other cancers. Researchers hope these vaccines could eventually provide powerful new ways to prevent and treat the disease.
The article provides a factual summary of medical research findings.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in